given in 179 pulses and repeated pulses were given in most patients at weekly intervals for one to three weeks to induce disease remission. A good response was noted in 37 of 55 (67%) patients assessed four weeks after the pulses. Only 20 patients needed more than one such course of three pulses of intravenous cyclophosphamide during the observation period. The non-responders were characterised by longstanding disease and irreversible histological findings in renal and muscle biopsy samples.
Patients with vasculitis, notably Wegener's granulomatosis, showed the most immediate response, and in most patients the amount of corticosteroids required was markedly reduced. In some patients steroids were completely stopped during the follow up period.
The most striking observation of this effective but more conservative regimen was the low incidence of major side effects such as neutropenia and infections. Patients and methods Table 1 gives the demographic data for these patients. The patients treated between April 1986 and April 1990 were all diagnosed as having serious progressive systemic diseases justifying treatment with intravenous cyclophosphamide. Forty five patients had previously not responded to treatment with prednisolone, 21 with azathioprine, eight with cyclophosphamide given by mouth, seven with methylprednisolone, four with antimalarial drugs, one with methotrexate, two with dapsone, one with penicillamine, and two with plasmapheresis either alone or in combination. The patients were followed up in the outpatients clinic for an average of 17 months (range 1-48 months) after the first course of intravenous cyclophosphamide. Intravenous cyclophosphamide (500 mg) was given in 100-500 ml saline, and each infusion was administered over one hour and was accompanied by vigorous hydration by mouth to promote frequent voiding of dilute urine in the first 24 hours after drug administration. To reduce bladder toxicity further, uromitexan (Mesna 100 mg) 15 16 was given in 200 of 211 pulses intravenously at the start of V) . In most of these patients the four week observation period was too short to see any dramatic changes in renal function, though two patients with renal impairment improved with decreases in the mean creatinine level from 487 to 273 ,tmol/l. The longer term follow up of these patients has been encouraging and has been reported elsewhere. 14 There was rapid improvement in all five patients with SLE with fever and all three with active serositis. All seven patients with SLE with cutaneous vasculitis responded rapidly to treatment within one to two weeks.
Systemic vasculitis
Thirteen patients with Wegener's granulomatosis, two with polyarteritis nodosa, and three with systemic vasculitis were included in the study. They were treated with a mean of 4-7 pulses (mean 1-17) and had a mean cumulative dose of 2-3 g cyclophosphamide (range 0 5-8-5). In patients with Wegener's granulomatosis the mean cumulative dose of intravenous cyclophosphamide (2 8 g ) and the mean number of pulses (6A4) were higher compared with the other patients in the study, reflecting aggressive and relapsing disease in many of these patients. Most patients responded promptly to treatment within two weeks and there was a dramatic improvement in all eight patients with cutaneous vasculitis, and six patients with fever, one with serositis, one with peripheral neuropathy, two with acute pulmonary infiltrates, five with ear, nose, and throat symptoms, one with acute deafness due to vasculitis, and one with loss of vision due to large granulomatous masses in the orbits. In this last patient sight was restored within the first two weeks of treatment and the orbital masses decreased in size over the following four months of treatment with pulse cyclophosphamide. Two patients with Wegener's granulomatosis had renal failure and their serum creatinine concentrations decreased from 478 to 396 and from 471 to 226 ,umol/l, respectively, within four weeks of the start of treatment with weekly doses of intravenous cyclophosphamide. Significant haematuria (4+) in dipstick testing in one patient with normal renal function was reduced to microscopic haematuria after three weekly pulses of intravenous cyclophosphamide.
Polymyositisldermatomyositis
Seven patients with polymyositis and dermatomyositis were treated with a mean of 3-6 pulses (range 2-5) and had a mean cumulative dose of cyclophosphamide of 1-6 g (range 0-8-2-5 g).
Intravenous pulse cyclophosphamide in connective tissue diseases Haematological side effects Table 3 shows that the neutrophil and lymphocyte counts were marginally reduced after two pulses followed by a more marked, but not statistically significant, decrease seen two weeks after the third pulse. A non-significant increase of neutrophils from 7 0 to 8 In this study using our 'St Thomas's Hospital regimen' of three weekly 500 mg intravenous pulses, neutropenia was rare. Lymphopenia and neutropenia induced by treatment was seen in only five of 105 courses of intravenous cyclophosphamide. The two serious episodes of lymphopenia and neutropenia followed by septicaemia may have also been associated with renal failure previously treated with azathioprine and intravenous cyclophosphamide. Lympho-penia was reversible in all five patients in whom it occurred.
Infectious complications were seen in 7-6% of our patients with lupus nephritis, though one patient died of a major infection. Herpes zoster was seen in only one patient. Infectious complications using low dose intravenous cyclophosphamide are therefore less common than reported for patients with lupus nephritis treated with higher doses of intravenous cyclophosphamide. 4 In a large prospective study4 it was concluded that the treatment of lupus nephritis with intravenous cyclophosphamide every third month together with low dose prednisolone reduced the risk of end stage renal failure, and that this treatment was superior to the alternative using high dose prednisolone or azathioprine by mouth. In another study treating lupus nephritis with low dose intravenous cyclophosphamide once a month,22 the urinary excretion of protein was reduced and creatinine clearance improved after six months of treatment, but the improvement in renal function was not reflected by a decrease in serum creatinine. By giving weekly low dose intravenous cyclophosphamide we found that serum creatinine levels began to decrease within four weeks of treatment in two patients with SLE with focal proliferative glomerulonephritis (WHO grade III) and two patients with Wegener's granulomatosis and renal failure.
We believe that this large preliminary study shows that low dose pulse cyclophosphamide regimens offer clear advantages over previously published regimens in the treatment of patients with active connective tissue diseases.
